Immutep sharpens efti technique round head and neck most cancers and delicate tissue sarcoma
Immutep Ltd (ASX:IMM) has outlined a extra targeted improvement technique for eftilagimod alfa (efti), concentrating on head and neck most cancers sufferers with unfavorable PD-L1 expression and the neoadjuvant remedy of sentimental tissue sarcoma (STS).
The biotechnology firm is making ready for its subsequent scientific trials, with research focused to start within the second half of 2027, topic to ultimate trial design, regulatory discussions, manufacturing timelines, partnering and out there sources.
The technique follows the early discontinuation of the TACTI-004 examine and an ongoing root trigger evaluation that has recognized delicate structural variations between efti manufactured at 200-litre and a couple of,000-litre scales.
Manufacturing variations beneath investigation
Immutep’s evaluation recognized variations together with a delicate variation in N-glycan construction between the efti utilized in TACTI-004 and materials utilized in earlier profitable scientific research.
The firm considers these variations doubtlessly related given the markedly totally different immune activation profile recorded in TACTI-004 and the examine’s sudden scientific end result.
Based on the investigation up to now, Immutep doesn’t consider the TACTI-004 end result will be defined by scientific components comparable to protocol design, treatment-arm imbalances or security findings, nor by trial execution points.
Immutep has consequently contracted a brand new 200-litre manufacturing run of efti. Ten GMP batches produced at that scale had been beforehand utilized in profitable Phase I and Phase II research together with TACTI-mel, TACTI-002 and INSIGHT-003, whereas TACTI-004 solely used materials manufactured on the 2,000-litre scale.
Clinical improvement narrows to 2 indications
Future registration-directed improvement will deal with head and neck squamous cell carcinoma (HNSCC) sufferers with a Combined Positive Score of lower than 1, the place Immutep has generated mature general survival information and efti holds US Food and Drug Administration Fast Track designation.
The second focus shall be efti within the neoadjuvant setting for STS, supported by constructive Phase II information through which the first endpoint was achieved. The FDA granted efti Orphan Drug Designation for STS in April 2026.
Licensing accomplice Dr. Reddy’s Laboratories has been consulted and helps the proposed technique, whereas Immutep has begun preliminary discussions with different events in regards to the improvement pathway.
“Based on the totality of proof generated with efti, we consider there’s a scientifically and clinically justified path to proceed its improvement. This contains scientific and translational information throughout a number of tumour sorts, constant proof of immune activation, encouraging ends in delicate tissue sarcoma and head and neck most cancers with CPS < 1, and constructive regulatory interactions,” Immutep CEO Marc Voigt mentioned.
“At the identical time, we totally recognise the importance of the TACTI-004 end result. Our root trigger evaluation stays ongoing, together with additional investigation of smaller variations recognized between product batches. We intend to use these learnings rigorously and focus future potential improvement on settings the place the scientific proof, organic rationale, time-to-market and unmet medical want are most compelling.”
About Immutep and efti
Efti is an immunotherapy designed to activate antigen-presenting cells by means of the MHC Class II pathway, stimulating each adaptive and innate immune responses in opposition to most cancers. Its security profile has supported mixtures with anti-PD-[L]1 immunotherapy, radiotherapy and chemotherapy.
Immutep is a clinical-stage biotechnology firm growing immunotherapies for most cancers and autoimmune ailments, with a portfolio centred on therapeutics concentrating on Lymphocyte Activation Gene-3 (LAG-3). Development of its agonist anti-LAG-3 antibody IMP761 for autoimmune illness is constant in line with beforehand disclosed plans.
